Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

573
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

644
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
644
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

141
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thin filament interaction and Ca<sup>2+</sup>-desensitization effect of the C-terminal end peptide of cardiac troponin T and loss of function in hypertrophic cardiomyopathy mutants.

Journal of molecular and cellular cardiology·2026
Same author

Delayed Abdominal Pain Following Botox® Bladder Injection Mimics Exercise-InducedTransient Abdominal Pain: A Case Report.

Pain medicine case reports·2026
Same author

Capturing Cardiomyocyte Cell-to-Cell Heterogeneity via Shotgun Single Cell Top-Down Proteomics.

bioRxiv : the preprint server for biology·2026
Same author

Quantifying the ∼75-95% of Peptides in DIA-MS Data Sets that Were Not Previously Quantified.

Journal of proteome research·2026
Same author

Multicenter HFpEF study identifies sex disparity linked with two discrete cardiac proteomic signatures.

bioRxiv : the preprint server for biology·2025
Same author

Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction.

Circulation·2025

Related Experiment Video

Updated: Jun 26, 2025

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
08:19

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes

Published on: June 22, 2020

6.4K

Fast skeletal myosin binding protein-C expression exacerbates dysfunction in heart failure.

James W McNamara, Taejeong Song, Perwez Alam

    Biorxiv : the Preprint Server for Biology
    |May 15, 2024
    PubMed
    Summary

    Elevated fast skeletal myosin binding protein-C (fMyBP-C) in the heart during heart failure is a pathological response, worsening cardiac dysfunction. Removing fMyBP-C protects against heart failure development, suggesting it as a therapeutic target.

    More Related Videos

    Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling
    08:29

    Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling

    Published on: August 1, 2016

    9.5K
    Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
    07:32

    Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

    Published on: May 25, 2022

    1.4K

    Related Experiment Videos

    Last Updated: Jun 26, 2025

    In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
    08:19

    In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes

    Published on: June 22, 2020

    6.4K
    Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling
    08:29

    Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling

    Published on: August 1, 2016

    9.5K
    Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
    07:32

    Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

    Published on: May 25, 2022

    1.4K

    Area of Science:

    • Cardiovascular Biology
    • Skeletal Muscle Physiology
    • Molecular Cardiology

    Background:

    • Heart failure involves complex genetic and protein remodeling.
    • Fast skeletal myosin binding protein-C (fMyBP-C) is upregulated in diseased hearts, but its role is unclear.
    • Cardiac myosin binding protein-C (cMyBP-C) and fMyBP-C share homology but have distinct functions.

    Approach:

    • Generated cardiac-specific fMyBP-C over-expression mice.
    • Crossed fMyBP-C over-expression mice into a cMyBP-C null model.
    • Utilized transverse aortic constriction (TAC) in fMyBP-C null mice to model heart failure.
    • Confirmed fMyBP-C upregulation in disease models using lineage tracing.

    Key Points:

    • Low-level fMyBP-C expression caused mild cardiac remodeling and sarcomere dysfunction.
    • Exclusive fMyBP-C expression exacerbated cardiac pathology in a heart failure model.
    • fMyBP-C null mice showed enhanced protection against heart failure post-TAC.
    • Differential regulation of the myosin super-relaxed state may underlie these effects.

    Conclusions:

    • Elevated fMyBP-C in diseased hearts is a pathological, not compensatory, response.
    • Targeting fMyBP-C upregulation may offer a therapeutic strategy for heart failure.
    • Understanding fMyBP-C's role provides insights into sarcomere function in cardiac disease.